Zydus Lifesciences Limited (IN:ZYDUSLIFE)
:ZYDUSLIFE
Want to see IN:ZYDUSLIFE full AI Analyst Report?
Total Valuation
Zydus Lifesciences Limited has a market cap or net worth of ₹1.05T. The enterprise value is ₹1.15T.
Market Cap₹1.05T
Enterprise Value₹1.15T
Share Statistics
Zydus Lifesciences Limited has 1,006,234,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,006,234,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Zydus Lifesciences Limited’s return on equity (ROE) is 0.19 and return on invested capital (ROIC) is 9.73%.
Return on Equity (ROE)0.19
Return on Assets (ROA)0.10
Return on Invested Capital (ROIC)9.73%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee10.08M
Profits Per Employee1.87M
Employee Count26,921
Asset Turnover0.52
Inventory Turnover2.33
Valuation Ratios
The current PE Ratio of Zydus Lifesciences Limited is 17.4. Zydus Lifesciences Limited’s PEG ratio is 1.53.
PE Ratio17.4
PS Ratio3.23
PB Ratio3.23
Price to Fair Value3.23
Price to FCF-72.89
Price to Operating Cash Flow110.21
PEG Ratio1.53
Income Statement
In the last 12 months, Zydus Lifesciences Limited had revenue of 271.48B and earned 50.40B in profits. Earnings per share was 50.09.
Revenue271.48B
Gross Profit140.30B
Operating Income57.87B
Pretax Income67.18B
Net Income50.40B
EBITDA71.95B
Earnings Per Share (EPS)50.09
Cash Flow
In the last 12 months, operating cash flow was 9.46B and capital expenditures -8.68B, giving a free cash flow of 785.00M billion.
Operating Cash Flow9.46B
Free Cash Flow785.00M
Free Cash Flow per Share0.78
Dividends & Yields
Zydus Lifesciences Limited pays an annual dividend of ₹11, resulting in a dividend yield of 1.19%
Dividend Per Share₹11
Dividend Yield1.19%
Payout Ratio22.04%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.49
52-Week Price Change15.95%
50-Day Moving Average922.58
200-Day Moving Average944.02
Relative Strength Index (RSI)69.44
Average Volume (3m)33.86K
Important Dates
Zydus Lifesciences Limited upcoming earnings date is Aug 12, 2026, TBA (Confirmed).
Last Earnings DateMay 19, 2026
Next Earnings DateAug 12, 2026
Ex-Dividend Date―
Financial Position
Zydus Lifesciences Limited as a current ratio of 1.27, with Debt / Equity ratio of 46.09%
Current Ratio1.27
Quick Ratio0.91
Debt to Market Cap0.13
Net Debt to EBITDA1.54
Interest Coverage Ratio13.18
Taxes
In the past 12 months, Zydus Lifesciences Limited has paid 15.95B in taxes.
Income Tax15.95B
Effective Tax Rate0.24
Enterprise Valuation
Zydus Lifesciences Limited EV to EBITDA ratio is 13.72, with an EV/FCF ratio of -82.10.
EV to Sales3.64
EV to EBITDA13.72
EV to Free Cash Flow-82.10
EV to Operating Cash Flow45.06
Balance Sheet
Zydus Lifesciences Limited has ₹70.69B in cash and marketable securities with ₹96.36B in debt, giving a net cash position of -₹25.68B billion.
Cash & Marketable Securities₹70.69B
Total Debt₹96.36B
Net Cash-₹25.68B
Net Cash Per Share-₹25.52
Tangible Book Value Per Share₹120.99
Margins
Gross margin is 56.26%, with operating margin of 21.31%, and net profit margin of 18.56%.
Gross Margin56.26%
Operating Margin21.31%
Pretax Margin24.75%
Net Profit Margin18.56%
EBITDA Margin26.50%
EBIT Margin21.31%
Analyst Forecast
The average price target for Zydus Lifesciences Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast16.81%
EPS Growth Forecast11.38%